文献速递核素与放射性配体治疗肿瘤 PET/CT

老年患者接受[177Lu]Lu-PSMA I&T放射性配体治疗:安全性、疗效及生存预后因素

Radioligand treatment with [177Lu]Lu-PSMA I&T in elderly Patients - Safety, efficacy, and prognostic factors for survival.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2025-08-25

研究评估56例中位年龄78岁(范围75-95)的转移性去势抵抗性前列腺癌患者接受[177Lu]Lu-PSMA I&T放射性配体治疗的安全性与疗效,未发生CTCAE III-V级毒性,中位总生存11个月,基线PSA、LDH、肝转移及PSA反应与生存相关。

要点

  • ≥75岁mCRPC患者接受[177Lu]Lu-PSMA I&T治疗未发生CTCAE III-V级毒性,中位OS为11个月。
  • 基线PSA(HR 1.001每ng/mL,P<0.10)和LDH(HR 1.008每U/L,P<0.01)升高与更短OS相关。
  • 肝转移患者生存更差(8 vs 21个月,HR 6.7,P<0.001),任何PSA反应预测更长OS(21 vs 7个月,HR 0.3,P<0.01)。

核心结论

  • [177Lu]Lu-PSMA I&T放射性配体治疗在≥75岁患者中耐受良好。
  • 较低基线PSA和LDH而非PSMA-TV预测更长OS。
  • 早期PSA反应与生存改善强相关。
  • 联合使用RECIP和PCWG3标准可优化疗效评估。

研究设计与样本

  • 研究纳入56例中位年龄78岁(范围75-95)的mCRPC男性患者接受RLT。
  • 不良事件按CTCAE v5.0分级。
  • 记录基线Gleason评分、血液参数(PSA、LDH)及转移部位(骨、淋巴结、肝、肺)。
  • 测量定量PET参数包括SUVmean、SUVpeak、SUVmax、PSMA-TV、TL-PSMA。
  • PET反应按RECIP 1.0评估,生化反应按PCWG3评估,采用单变量和多变量Cox回归及Kaplan-Meier曲线分析OS相关因素。

主要发现

  • 未发生CTCAE III-V级毒性;I/II级血液学事件包括贫血(23.2%)、白细胞减少(18.6%)和血小板减少(9.3%);eGFR下降2.5%(I/II级占18.6%)。
  • 中位OS为11个月;60.7%患者死亡。
  • 74.4%患者(32/43)出现PSA下降(中位-58%;14/43≥50%)。
  • 基线PSA较高(HR 1.001每ng/mL;P<0.10)和LDH较高(HR 1.008每U/L;P<0.01)与更短OS相关。
  • RECIP和PCWG3均判定为进展的患者OS短于其他患者(11 vs 22个月;HR 3.3;P<0.01);任何PSA反应预测更长OS(21 vs 7个月;HR 0.3;P<0.01);肝转移患者生存更差(8 vs 21个月;HR 6.7;P<0.001)。

关键数值与推荐

  • 不良事件分级采用CTCAE v5.0。
  • PET反应评估采用RECIP 1.0。
  • 生化反应评估采用PCWG3。
  • PSA反应定义为任何PSA下降,其中≥50%下降单独报告。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We aimed to evaluate the safety and efficacy to explore predictors of prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) with [¹⁷⁷Lu]Lu-PSMA I&T in metastatic castration-resistant prostate cancer (mCRPC) patients aged ≥ 75 and explored baseline predictors of overall survival (OS). MATERIALS AND METHODS: 56 men (median age 78, range 75-95) were treated with RLT. Adverse events were graded according to the Common Terminology Criteria for Adverse Events (CTCAE) v5.0. Baseline Gleason score, blood parameters (PSA, LDH), and sites of metastases (bone, lymph nodes, liver, lung) were recorded. Quantitative PET parameters such as SUVmean (mean standardized uptake value), SUVpeak (peak standardized uptake value), SUVmax (maximum standardized uptake value), PSMA-TV (PSMApositive tumor volume), TL-PSMA (total lesion PSMA) were measured. PET response was assessed by RECIP 1.0 (response evaluation criteria in PSMA imaging); biochemical response by PCWG3 (prostate cancer working group 3). Associations with OS were analyzed via uni- and multivariable Cox regression and Kaplan-Meier curves. RESULTS: No CTCAE grade III-V toxicities occurred. Grade I/II hematologic events included anemia (23.2%), leukocytopenia (18.6%) and thrombocytopenia (9.3%); eGFR declined by 2.5% (grade I/II in 18.6%). Median OS was 11 months; 60.7% of patients died. 74.4% of patients (32/43) showed PSA declines (median - 58%; 14/43 ≥ 50%). Higher baseline PSA (HR 1.001 per ng/mL; P < 0.10) and LDH (HR 1.008 per U/L; P < 0.01) were associated with shorter OS. Patients with progressive disease by both RECIP and PCWG3 had shorter OS than others (11 vs. 22 months; HR 3.3; P < 0.01). Any PSA response predicted longer OS (21 vs. 7 months; HR 0.3; P < 0.01). Presence of liver metastases portended poorer survival (8 vs. 21 months; HR 6.7; P < 0.001). CONCLUSION: [¹⁷⁷Lu]Lu-PSMA I&T RLT is well tolerated in patients ≥ 75 years. Lower baseline PSA and LDH but not PSMA-TV predict longer OS. Early PSA response strongly correlates with improved survival. Combined use of RECIP and PCWG3 criteria optimizes response assessment.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Schwinger M, Kalogirou C, Scheper V, et al. Radioligand treatment with [177Lu]Lu-PSMA I&T in elderly Patients - Safety, efficacy, and prognostic factors for survival. Eur J Nucl Med Mol Imaging. 2025. PMID: 40851054. doi:10.1007/s00259-025-07519-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。